Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

NCT00546364 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

62

Enrollment

INDUSTRY

Sponsor class

Stopped Slow Accrual

Conditions

Breast Neoplasms

Interventions

DRUG: Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2
DRUG: Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2
DRUG: Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2

Sponsor

R-Pharm